- Wealth Management
- Funds
  - Mutual Funds
  - Alternative Investment Funds
- Structured products
  - Structured Investment products
- Corporate Finance
  - Corporate Finance services
  - Transactions
- Equity Research
- Rewards and incentive plans
  - Rewards and incentive plans
Mutual Funds

Founded alongside the birth of the modern Nordic fixed income and equity capital markets at the end of the 1980s Evli Fund Management Company is today the best fund house in the Nordics, according to both Lipper and Morningstar.
Mutual Funds

Become a customer

Is your need to invest and save independently or do you want help from professionals? You can easily open a customer relationship online with your personal banking codes.
Become a client
Responsible Evli

Responsible operations enable us to create long-term value and to remain competitive and successful in the changing global operating environment.
Responsible Evli

Responsible investing

Responsibility is at the core of Evli's strategy and is based on transparency and openness.
Responsible investing

Responsible employer

Our approach to responsibility and the way we work are based on Evli’s values: entrepreneurship, valuable relationships, learning, and integrity.
Responsible employer
Insights
- About us
- Offices
- People
- Careers
About us

We draw on our heritage, broad expertise and Nordic values to grow and manage wealth for institutions, corporations and private persons in a responsible way.
About us

Our offices

Evli has offices in Finland and Sweden.
Offices

Our people

Our experts take care of your wealth. We aim to build a long-term relationship with you.
People

Careers

We want to be the best partner for our clients and the number one choice for both current and new employees.
Careers
Become a client

Investor Relations

My Evli

Diaclone divested to Medix Biochemica

Name: Evli
Price range: $

Divestment to Medix Biochemica

May 2021

Sector: Healthcare

Service: M&A

Our role

Assisted our French partner firm DDA & Company on the sale of Diaclone to Medix Biochemica Group

Buyer

Medix Biochemica Group is a global, market-leading supplier of critical raw materials to the in vitro diagnostics (IVD) industry. In 2020, Medix Biochemica Group employed more than 200 professionals worldwide and had revenues of EUR 45 million. Headquartered in Finland and local teams in the US, Europe, and Asia.

Target

Diaclone, founded in 1986, is a prominent provider of monoclonal antibodies in the areas of inflammation, oncology, and immunology. In 2020, Diaclone employed a team of c. 25 professionals in Besançon, France